DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Sodium bicarbonate |
DMMU6BJ
|
Minor |
Altered absorption of Halazepam due to GI dynamics variation caused by Sodium bicarbonate. |
Acidosis [5C73]
|
[3] |
Oliceridine |
DM6MDCF
|
Major |
Additive CNS depression effects by the combination of Halazepam and Oliceridine. |
Acute pain [MG31]
|
[4] |
Dalfopristin |
DM4LTKV
|
Moderate |
Decreased metabolism of Halazepam caused by Dalfopristin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[5] |
Clarithromycin |
DM4M1SG
|
Moderate |
Decreased metabolism of Halazepam caused by Clarithromycin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[6] |
Dihydrocodeine |
DMB0FWL
|
Major |
Additive CNS depression effects by the combination of Halazepam and Dihydrocodeine. |
Chronic pain [MG30]
|
[4] |
Propofol |
DMB4OLE
|
Moderate |
Additive cardiorespiratory depression effects by the combination of Halazepam and Propofol. |
Corneal disease [9A76-9A78]
|
[7] |
Alfentanil |
DMVO0UB
|
Major |
Additive CNS depression effects by the combination of Halazepam and Alfentanil. |
Corneal disease [9A76-9A78]
|
[8] |
Remifentanil |
DMZTXCH
|
Major |
Additive CNS depression effects by the combination of Halazepam and Remifentanil. |
Corneal disease [9A76-9A78]
|
[8] |
Ethanol |
DMDRQZU
|
Moderate |
Additive CNS depression effects by the combination of Halazepam and Ethanol. |
Cystitis [GC00]
|
[9] |
Nefazodone |
DM4ZS8M
|
Moderate |
Decreased metabolism of Halazepam caused by Nefazodone mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[10] |
Esketamine |
DMVU687
|
Moderate |
Additive CNS depression effects by the combination of Halazepam and Esketamine. |
Depression [6A70-6A7Z]
|
[11] |
SODIUM CITRATE |
DMHPD2Y
|
Minor |
Altered absorption of Halazepam due to GI dynamics variation caused by SODIUM CITRATE. |
Discovery agent [N.A.]
|
[3] |
Fosphenytoin |
DMOX3LB
|
Moderate |
Increased metabolism of Halazepam caused by Fosphenytoin mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[12] |
Isoniazid |
DM5JVS3
|
Moderate |
Decreased metabolism of Halazepam caused by Isoniazid mediated inhibition of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[13] |
Rifampin |
DMA8J1G
|
Minor |
Increased metabolism of Halazepam caused by Rifampin mediated induction of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[14] |
Fosamprenavir |
DM4W9B3
|
Moderate |
Decreased metabolism of Halazepam caused by Fosamprenavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[15] |
Didanosine |
DMI2QPE
|
Minor |
Altered absorption of Halazepam due to GI dynamics variation caused by Didanosine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[3] |
Probenecid |
DMMFWOJ
|
Minor |
Decreased metabolism of Halazepam caused by Probenecid. |
Inborn purine/pyrimidine/nucleotide metabolism error [5C55]
|
[16] |
Allopregnanolone |
DMNLHAC
|
Moderate |
Additive CNS depression effects by the combination of Halazepam and Allopregnanolone. |
Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]
|
[17] |
Lasmiditan |
DMXLVDT
|
Moderate |
Additive CNS depression effects by the combination of Halazepam and Lasmiditan. |
Migraine [8A80]
|
[18] |
Flibanserin |
DM70DTN
|
Moderate |
Additive CNS depression effects by the combination of Halazepam and Flibanserin. |
Mood disorder [6A60-6E23]
|
[19] |
Thalidomide |
DM70BU5
|
Moderate |
Additive CNS depression effects by the combination of Halazepam and Thalidomide. |
Multiple myeloma [2A83]
|
[20] |
Teduglutide |
DMYOAKS
|
Moderate |
Altered absorption of Halazepam caused by Teduglutide. |
Neonatal malabsorption syndrome [KB89]
|
[21] |
Apraclonidine |
DMO4PVE
|
Moderate |
Additive CNS depression effects by the combination of Halazepam and Apraclonidine. |
Optic nerve disorder [9C40]
|
[22] |
Oxymorphone |
DM65AGJ
|
Major |
Additive CNS depression effects by the combination of Halazepam and Oxymorphone. |
Pain [MG30-MG3Z]
|
[8] |
Levorphanol |
DMGS80V
|
Major |
Additive CNS depression effects by the combination of Halazepam and Levorphanol. |
Pain [MG30-MG3Z]
|
[8] |
Nalbuphine |
DMOSQGU
|
Major |
Additive CNS depression effects by the combination of Halazepam and Nalbuphine. |
Pain [MG30-MG3Z]
|
[8] |
Buprenorphine |
DMPRI8G
|
Major |
Additive CNS depression effects by the combination of Halazepam and Buprenorphine. |
Pain [MG30-MG3Z]
|
[23] |
Hydrocodone |
DMQ2JO5
|
Major |
Additive CNS depression effects by the combination of Halazepam and Hydrocodone. |
Pain [MG30-MG3Z]
|
[8] |
Temsirolimus |
DMS104F
|
Moderate |
Increased plasma concentrations of Halazepam and Temsirolimus due to competitive inhibition of the same metabolic pathway. |
Renal cell carcinoma [2C90]
|
[24] |
Fentanyl |
DM8WAHT
|
Major |
Additive CNS depression effects by the combination of Halazepam and Fentanyl. |
Sensation disturbance [MB40]
|
[8] |
Armodafinil |
DMGB035
|
Minor |
Increased metabolism of Halazepam caused by Armodafinil mediated induction of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[25] |
Sirolimus |
DMGW1ID
|
Moderate |
Increased plasma concentrations of Halazepam and Sirolimus due to competitive inhibition of the same metabolic pathway. |
Transplant rejection [NE84]
|
[24] |
Tacrolimus |
DMZ7XNQ
|
Moderate |
Increased plasma concentrations of Halazepam and Tacrolimus due to competitive inhibition of the same metabolic pathway. |
Transplant rejection [NE84]
|
[24] |
Amiodarone |
DMUTEX3
|
Minor |
Potentiate the pharmacologic effects by the combination of Halazepam and Amiodarone. |
Ventricular tachyarrhythmia [BC71]
|
[26] |
----------- |
|
|
|
|
|